Biotech and Medtech Stocks Surge in After-Hours Trading for Major Companies
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 15 2025
0mins
Should l Buy PEN?
Source: NASDAQ.COM
Surge in Healthcare Stocks: On September 12, several healthcare and biotech stocks, including Penumbra, Check-Cap, Adaptimmune Therapeutics, and NewAmsterdam Pharma, saw significant after-hours trading gains, driven by strategic announcements and clinical milestones, despite some movements occurring without direct news.
Penumbra's Stock Performance: Penumbra Inc. experienced a rebound in after-hours trading, rising 6.28% to $289.86, following a decline during regular hours. The company raised its full-year revenue guidance and appointed a new president, indicating confidence in its growth trajectory.
Check-Cap's Merger Announcement: Check-Cap Ltd. saw its stock soar by 191.22% after announcing a merger with MBody AI, which aims to enhance its colorectal cancer screening technology with AI capabilities, potentially transforming its strategic direction.
NewAmsterdam Pharma's Regulatory Progress: NewAmsterdam Pharma's shares rose 8.23% after-hours, driven by positive investor sentiment regarding its lead candidate obicetrapib and recent regulatory milestones, including accepted Marketing Authorization Applications by the EMA and promising trial data related to Alzheimer's disease biomarkers.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PEN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PEN
Wall Street analysts forecast PEN stock price to rise
15 Analyst Rating
14 Buy
1 Hold
0 Sell
Strong Buy
Current: 328.200
Low
266.00
Averages
344.64
High
388.00
Current: 328.200
Low
266.00
Averages
344.64
High
388.00
About PEN
Penumbra, Inc. is a thrombectomy company, which is focused on developing technologies for challenging medical conditions, such as ischemic stroke, venous thromboembolism, such as pulmonary embolism, and acute limb ischemia. The Company's broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe. It focuses on developing, manufacturing and marketing novel products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. Some of the conditions it focuses on are Pulmonary Embolism, Deep Vein Thrombosis, Acute Limb Ischemia, Ischemic Stroke, Acute Coronary Syndrome, and Clot associated with Arteriovenous Graft or Fistula. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Monteverde Law Firm Investigates Multiple Mergers
- Shareholder Compensation Investigation: Monteverde Law Firm is investigating the transaction between Thermon Group Holdings and CECO Environmental, where Thermon shareholders may choose to receive $10 in cash and 0.6840 shares of CECO stock per share, or $63.89 in cash, or 0.8110 shares of CECO stock, which will directly impact shareholder financial returns.
- Penumbra Transaction Details: In the deal involving Penumbra, Inc. and Boston Scientific Corporation, Penumbra shareholders are expected to receive either 3.8721 shares of Boston Scientific common stock or $374 in cash per share, providing significant cash flow and potential stock appreciation for shareholders.
- Brink's Merger Proposal: In the merger between Brink’s Company and NCR Atleos Corporation, NCR Atleos shareholders are expected to receive $30 in cash and 0.1574 shares of Brink’s common stock per share, offering NCR shareholders stable cash returns and future equity appreciation opportunities.
- Allegiant Merger Outlook: The merger between Allegiant Travel Company and Sun Country Airlines is expected to result in Allegiant shareholders owning approximately 67% of the combined company, significantly enhancing Allegiant's competitiveness and market share in the airline industry.
See More
US Supreme Court Strikes Down Trump's Tariff Regime
- Market Reaction: The US Supreme Court's 6-3 ruling against Trump's tariff regime led to a swift market rebound, with the S&P 500 rising 0.7%, indicating a moderate investor optimism regarding the policy shift despite initial losses.
- Limited Economic Impact: The ruling affects approximately 60% of tariffs under the IEEPA, and while it could lead to refund requests totaling up to $175 billion, the overall economic impact is deemed limited, resulting in a muted market response.
- Oil Price Fluctuations: Oil prices surged about 5.5% over the past week due to escalating tensions in the Middle East, with projections suggesting a potential increase of $10 to $15 per barrel if the US engages in military action, highlighting the significant geopolitical risks to energy markets.
- Upcoming Economic Data: The forthcoming Producer Price Index (PPI) will provide investors with crucial insights into inflation trends, which are expected to influence the Federal Reserve's monetary policy, particularly as inflation remains persistently above target levels.
See More
Investigation Alerts for Multiple Company Mergers
- RAPT Acquisition Investigation: RAPT Therapeutics is set to be acquired by GlaxoSmithKline for $58 per share, totaling an estimated equity value of $2.2 billion, with investigations focusing on whether the board failed to conduct a fair process, potentially impacting shareholder rights.
- Calavo Merger Details: Calavo Growers will be acquired by Mission Produce, with shareholders receiving $27 per share, including $14.85 in cash and 0.9790 shares of Mission, valuing the transaction at approximately $430 million, while investigations examine if the board breached fiduciary duties to shareholders.
- Penumbra Acquisition Status: Penumbra will be acquired by Boston Scientific in a deal valuing the company at $374 per share, reflecting an enterprise value of about $14.5 billion, with investigations looking into whether the board ensured a fair process, potentially affecting shareholder interests.
- FONAR Merger Investigation: FONAR Corporation is to be acquired by FONAR, LLC for $19 per share in an all-cash transaction, with investigations questioning whether the board failed to conduct a fair process, which could impact shareholder rights.
See More
Boston Scientific Alerts Recall of AXIOS Stents Amid 167 Serious Injuries
- Recall Notification: Boston Scientific issued a recall notice on December 19, 2025, instructing customers to immediately halt the use and distribution of certain AXIOS stents and electrocautery-enhanced delivery systems due to high-risk concerns during procedures, potentially damaging the company's reputation and market trust.
- Safety Hazard Reports: As of December 23, Boston Scientific reported 167 serious injuries and three deaths associated with the issue, indicating difficulties in stent deployment and expansion that may extend procedure times and require additional interventions, thus increasing healthcare costs.
- Institutional Response Measures: The company instructed healthcare facilities to remove affected products from inventory and store them securely, while also requiring hospital systems to notify other facilities within their networks to ensure visibility of the alert for all users and handlers, thereby mitigating potential risks.
- Regulatory Review Updates: The FDA is actively reviewing information related to this potentially high-risk device issue and has committed to providing updates as significant new details become available, reflecting the regulatory body's heightened focus on medical device safety.
See More
RAPT Therapeutics to be Acquired by GSK for $58 per Share Amid Shareholder Investigation
- Acquisition Overview: RAPT Therapeutics is set to be acquired by GlaxoSmithKline for $58 per share, representing an estimated aggregate equity value of $2.2 billion, prompting an investigation into whether the board breached its fiduciary duties, potentially impacting shareholder rights.
- Calavo Acquisition Details: Calavo Growers will be acquired by Mission Produce, with shareholders receiving $27 per share, including $14.85 in cash and 0.9790 shares of Mission, valuing the enterprise at approximately $430 million, while an investigation questions the fairness of the board's process.
- Penumbra Acquisition Status: Penumbra will be acquired by Boston Scientific in a deal valued at $374 per share, reflecting an enterprise value of about $14.5 billion, with investigations focusing on whether the board failed to ensure fair treatment for shareholders.
- FONAR Acquisition Investigation: FONAR Corporation will be acquired for $19 per share in an all-cash transaction, with investigations examining whether the board neglected its fiduciary duties during the acquisition process, which could affect shareholder interests.
See More
Moderna Raises 2025 Revenue Forecast to $1.9 Billion, Stock Surges 20%
- Banking Earnings Season: Major banks including Citigroup, Wells Fargo, Bank of America, Goldman Sachs, JP Morgan, and Morgan Stanley reported EPS beats, with Morgan Stanley and Goldman Sachs gaining 5.8% and 4.6% respectively post-earnings, indicating strong market confidence in their performance.
- CoreWeave's Strong Performance: CoreWeave's stock surged 12.2% on Monday and has rallied over 28% in the past week, driven by CEO comments defending GPU lifespan concerns, with analysts noting ongoing strong demand and an expanding customer base.
- Moderna's Revenue Forecast Increase: Moderna's stock rose 17% on Tuesday and is up 20% for the week after raising its 2025 revenue forecast to approximately $1.9 billion, exceeding expectations, with analysts highlighting improved financial discipline and significant growth catalysts ahead.
- Penumbra Acquisition Deal: Penumbra's stock climbed 10.8% on Thursday following Boston Scientific's agreement to acquire the company for approximately $14.5 billion, with shareholders set to receive $374 per share, representing a 19.3% premium, and analysts see clear strategic rationale for the acquisition.
See More
Monteverde Law Firm Investigates Multiple Mergers
- Shareholder Compensation Investigation: Monteverde Law Firm is investigating the transaction between Thermon Group Holdings and CECO Environmental, where Thermon shareholders may choose to receive $10 in cash and 0.6840 shares of CECO stock per share, or $63.89 in cash, or 0.8110 shares of CECO stock, which will directly impact shareholder financial returns.
- Penumbra Transaction Details: In the deal involving Penumbra, Inc. and Boston Scientific Corporation, Penumbra shareholders are expected to receive either 3.8721 shares of Boston Scientific common stock or $374 in cash per share, providing significant cash flow and potential stock appreciation for shareholders.
- Brink's Merger Proposal: In the merger between Brink’s Company and NCR Atleos Corporation, NCR Atleos shareholders are expected to receive $30 in cash and 0.1574 shares of Brink’s common stock per share, offering NCR shareholders stable cash returns and future equity appreciation opportunities.
- Allegiant Merger Outlook: The merger between Allegiant Travel Company and Sun Country Airlines is expected to result in Allegiant shareholders owning approximately 67% of the combined company, significantly enhancing Allegiant's competitiveness and market share in the airline industry.
See More
US Supreme Court Strikes Down Trump's Tariff Regime
- Market Reaction: The US Supreme Court's 6-3 ruling against Trump's tariff regime led to a swift market rebound, with the S&P 500 rising 0.7%, indicating a moderate investor optimism regarding the policy shift despite initial losses.
- Limited Economic Impact: The ruling affects approximately 60% of tariffs under the IEEPA, and while it could lead to refund requests totaling up to $175 billion, the overall economic impact is deemed limited, resulting in a muted market response.
- Oil Price Fluctuations: Oil prices surged about 5.5% over the past week due to escalating tensions in the Middle East, with projections suggesting a potential increase of $10 to $15 per barrel if the US engages in military action, highlighting the significant geopolitical risks to energy markets.
- Upcoming Economic Data: The forthcoming Producer Price Index (PPI) will provide investors with crucial insights into inflation trends, which are expected to influence the Federal Reserve's monetary policy, particularly as inflation remains persistently above target levels.
See More
Investigation Alerts for Multiple Company Mergers
- RAPT Acquisition Investigation: RAPT Therapeutics is set to be acquired by GlaxoSmithKline for $58 per share, totaling an estimated equity value of $2.2 billion, with investigations focusing on whether the board failed to conduct a fair process, potentially impacting shareholder rights.
- Calavo Merger Details: Calavo Growers will be acquired by Mission Produce, with shareholders receiving $27 per share, including $14.85 in cash and 0.9790 shares of Mission, valuing the transaction at approximately $430 million, while investigations examine if the board breached fiduciary duties to shareholders.
- Penumbra Acquisition Status: Penumbra will be acquired by Boston Scientific in a deal valuing the company at $374 per share, reflecting an enterprise value of about $14.5 billion, with investigations looking into whether the board ensured a fair process, potentially affecting shareholder interests.
- FONAR Merger Investigation: FONAR Corporation is to be acquired by FONAR, LLC for $19 per share in an all-cash transaction, with investigations questioning whether the board failed to conduct a fair process, which could impact shareholder rights.
See More
Boston Scientific Alerts Recall of AXIOS Stents Amid 167 Serious Injuries
- Recall Notification: Boston Scientific issued a recall notice on December 19, 2025, instructing customers to immediately halt the use and distribution of certain AXIOS stents and electrocautery-enhanced delivery systems due to high-risk concerns during procedures, potentially damaging the company's reputation and market trust.
- Safety Hazard Reports: As of December 23, Boston Scientific reported 167 serious injuries and three deaths associated with the issue, indicating difficulties in stent deployment and expansion that may extend procedure times and require additional interventions, thus increasing healthcare costs.
- Institutional Response Measures: The company instructed healthcare facilities to remove affected products from inventory and store them securely, while also requiring hospital systems to notify other facilities within their networks to ensure visibility of the alert for all users and handlers, thereby mitigating potential risks.
- Regulatory Review Updates: The FDA is actively reviewing information related to this potentially high-risk device issue and has committed to providing updates as significant new details become available, reflecting the regulatory body's heightened focus on medical device safety.
See More
RAPT Therapeutics to be Acquired by GSK for $58 per Share Amid Shareholder Investigation
- Acquisition Overview: RAPT Therapeutics is set to be acquired by GlaxoSmithKline for $58 per share, representing an estimated aggregate equity value of $2.2 billion, prompting an investigation into whether the board breached its fiduciary duties, potentially impacting shareholder rights.
- Calavo Acquisition Details: Calavo Growers will be acquired by Mission Produce, with shareholders receiving $27 per share, including $14.85 in cash and 0.9790 shares of Mission, valuing the enterprise at approximately $430 million, while an investigation questions the fairness of the board's process.
- Penumbra Acquisition Status: Penumbra will be acquired by Boston Scientific in a deal valued at $374 per share, reflecting an enterprise value of about $14.5 billion, with investigations focusing on whether the board failed to ensure fair treatment for shareholders.
- FONAR Acquisition Investigation: FONAR Corporation will be acquired for $19 per share in an all-cash transaction, with investigations examining whether the board neglected its fiduciary duties during the acquisition process, which could affect shareholder interests.
See More
Moderna Raises 2025 Revenue Forecast to $1.9 Billion, Stock Surges 20%
- Banking Earnings Season: Major banks including Citigroup, Wells Fargo, Bank of America, Goldman Sachs, JP Morgan, and Morgan Stanley reported EPS beats, with Morgan Stanley and Goldman Sachs gaining 5.8% and 4.6% respectively post-earnings, indicating strong market confidence in their performance.
- CoreWeave's Strong Performance: CoreWeave's stock surged 12.2% on Monday and has rallied over 28% in the past week, driven by CEO comments defending GPU lifespan concerns, with analysts noting ongoing strong demand and an expanding customer base.
- Moderna's Revenue Forecast Increase: Moderna's stock rose 17% on Tuesday and is up 20% for the week after raising its 2025 revenue forecast to approximately $1.9 billion, exceeding expectations, with analysts highlighting improved financial discipline and significant growth catalysts ahead.
- Penumbra Acquisition Deal: Penumbra's stock climbed 10.8% on Thursday following Boston Scientific's agreement to acquire the company for approximately $14.5 billion, with shareholders set to receive $374 per share, representing a 19.3% premium, and analysts see clear strategic rationale for the acquisition.
See More
